DEXACEN-4 Drug Patent Profile
Which patents cover Dexacen-4, and what generic alternatives are available?
Dexacen-4 is a drug marketed by Cent Pharms and is included in one NDA.
The generic ingredient in DEXACEN-4 is dexamethasone sodium phosphate. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the dexamethasone sodium phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dexacen-4
A generic version of DEXACEN-4 was approved as dexamethasone sodium phosphate by HIKMA on September 7th, 1982.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DEXACEN-4?
- What are the global sales for DEXACEN-4?
- What is Average Wholesale Price for DEXACEN-4?
Summary for DEXACEN-4
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 82 |
| Clinical Trials: | 1 |
| Patent Applications: | 6,324 |
| DailyMed Link: | DEXACEN-4 at DailyMed |
Recent Clinical Trials for DEXACEN-4
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 1 |
US Patents and Regulatory Information for DEXACEN-4
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cent Pharms | DEXACEN-4 | dexamethasone sodium phosphate | INJECTABLE;INJECTION | 084342-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
